{{Drugbox
| Watchedfields = changed
| verifiedrevid = 459983915
| IUPAC_name = (5&prime;α)-2-Bromo-12&prime;-hydroxy-5&prime;-(2-methylpropyl)-3&prime;,6&prime;,18-trioxo-2&prime;-(propan-2-yl)ergotaman
| image = Bromocriptine.svg
| image2 = Bromocriptine ball-and-stick.png
<!--Clinical data-->
| tradename = Originally Parlodel, subsequently many<ref name=brands/>
| Drugs.com = {{drugs.com|monograph|parlodel}},{{drugs.com|international|brotin}}
| MedlinePlus = a682079
| pregnancy_AU = A
| pregnancy_US = B
| legal_AU = S4
| legal_CA = Rx-only
| legal_US = Rx-only
| legal_UK = POM
| routes_of_administration = oral, intravenous 
<!--Pharmacokinetic data-->
| bioavailability = 28% of oral dose absorbed
| metabolism = Extensively liver-mediated
| elimination_half-life = 12-14 hours
| excretion = 85% bile (faeces), 2.5-5.5% urine
<!--Identifiers-->
| synonyms = 2-Bromoergocriptine
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 25614-03-3
| ATC_prefix = G02
| ATC_suffix = CB01
| ATC_supplemental = {{ATC|N04|BC01}}
| PubChem = 31101
| IUPHAR_ligand = 35
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01200
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 28858
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3A64E3G5ZO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03165
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3181
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 493
<!--Chemical data-->
| C=32 | H=40 | Br=1 | N=5 | O=5
| molecular_weight = 654.595 g/mol
| smiles = BrC1=C(C[C@H]2N(C)C3)C4=C(C=CC=C4C2=C[C@H]3C(N[C@]5(C(C)C)O[C@@]6(N([C@@H](CC(C)C)C(N7CCC[C@H]76)=O)C5=O)O)=O)N1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OZVBMTJYIDMWIL-AYFBDAFISA-N
}}
'''Bromocriptine''' (originally marketed as  '''Parlodel''', subsequently under many names)<ref name=brands/> is an [[ergoline]] derivative, is a [[dopamine agonist]] that is used in the treatment of [[pituitary]] [[tumors]], [[Parkinson's disease]] (PD), [[hyperprolactinaemia]], [[neuroleptic malignant syndrome]], and [[Diabetes mellitus type 2|type 2 diabetes]].

== Indications ==
Bromocriptine is used to treat [[acromegaly]] and conditions associated with [[hyperprolactinemia]] like [[amenorrhea]], infertility, and [[hypogonadism]], prolactin-secreting [[adenomas]]; it is also used to prevent [[ovarian hyperstimulation syndrome]].<ref name=OlderLabel>{{cite web|title=Bromocriptine mesylate tablets -- original uses |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf|publisher=FDA|date=January 2012}} For label updates see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017962 FDA index page for NDA 017962]</ref><ref>{{cite journal|last1=Molitch|first1=ME|title=Diagnosis and Treatment of Pituitary Adenomas: A Review.|journal=JAMA|date=7 February 2017|volume=317|issue=5|pages=516–524|doi=10.1001/jama.2016.19699|pmid=28170483}}</ref><ref>{{cite journal|last1=Tang|first1=H|last2=Mourad|first2=S|last3=Zhai|first3=SD|last4=Hart|first4=RJ|title=Dopamine agonists for preventing ovarian hyperstimulation syndrome.|journal=The Cochrane database of systematic reviews|date=30 November 2016|volume=11|pages=CD008605|doi=10.1002/14651858.CD008605.pub3|pmid=27901279}}</ref>

It is also used to treat [[Parkinson's disease]].<ref name=OlderLabel/>

Since the late 1980s it has been used, off-label, to reduce the symptoms of cocaine withdrawal but the evidence for this use is poor.<ref>{{cite journal|last1=Minozzi|first1=S|last2=Amato|first2=L|last3=Pani|first3=PP|last4=Solimini|first4=R|last5=Vecchi|first5=S|last6=De Crescenzo|first6=F|last7=Zuccaro|first7=P|last8=Davoli|first8=M|title=Dopamine agonists for the treatment of cocaine dependence.|journal=The Cochrane database of systematic reviews|date=27 May 2015|issue=5|pages=CD003352|doi=10.1002/14651858.CD003352.pub4|pmid=26014366}}</ref>

A quick-release formulation of bromocriptine is also used to treat [[type 2 diabetes]].<ref name=DiabetesLabel>{{cite web|title=Bromocriptine mesylate tablet label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf|publisher=FDA|date=February 2017}}. For label updates see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020866 FDA index page for NDA 020866]</ref><ref>{{cite journal|last1=Garber|first1=AJ|last2=Blonde|first2=L|last3=Bloomgarden|first3=ZT|last4=Handelsman|first4=Y|last5=Dagogo-Jack|first5=S|title=The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.|journal=Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|date=2013|volume=19|issue=1|pages=100–6|doi=10.4158/EP12325.OR|pmid=23337160}}</ref><ref>{{cite journal|last1=Liang|first1=W|last2=Gao|first2=L|last3=Li|first3=N|last4=Wang|first4=B|last5=Wang|first5=L|last6=Wang|first6=Y|last7=Yang|first7=H|last8=You|first8=L|last9=Hou|first9=J|last10=Chen|first10=S|last11=Zhu|first11=H|last12=Jiang|first12=Y|last13=Pan|first13=H|title=Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis.|journal=Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme|date=October 2015|volume=47|issue=11|pages=805–12|doi=10.1055/s-0035-1559684|pmid=26332757}}</ref>

== Side effects ==
Most frequent side effects are nausea, orthostatic hypotension, headaches, and vomiting through stimulation of the brainstem vomiting centre.<ref>{{Cite journal
| pages = 25–51
| year = 1986
| pmid = 3516579
| doi = 10.1185/03007998609111089
| issue = 1
| volume = 10 | first1 = C.
| title = The safety of bromocriptine in long-term use: a review of the literature
| journal = Current medical research and opinion
| last1 = Weil
}}</ref> Vasospasms with serious consequences such as myocardial infarction and stroke that have been reported in  connection with the [[puerperium]], appear to be extremely rare events.<ref>{{Cite journal
| last1 = Iffy
| first1 = L
| last2 = McArdle
| first2 = JJ
| last3 = Ganesh
| first3 = V
| last4 = Hopp
| first4 = L
| title = Bromocriptine related atypical vascular accidents postpartum identified through medicolegal reviews
| journal = Medicine and law
| volume = 15
| issue = 1
| pages = 127–34
| year = 1996
| pmid = 8691994
}}</ref>  Peripheral vasospasm (of the fingers or toes) can cause [[Raynaud's Phenomenon]]. 
Bromocriptine use has been anecdotally associated with causing or worsening [[psychosis|psychotic]] symptoms (its mechanism is in opposition of most antipsychotics, whose mechanisms generally block dopamine).<ref>{{Cite journal
| issue = 1
| pages = 87–95
| year = 1995
| pmid = 7701022
| volume = 66
| journal = The Psychiatric quarterly
| last1 = Boyd
| title = Bromocriptine and psychosis: a literature review
| doi = 10.1007/BF02238717 | first1 = A.
}}</ref>
[[Pulmonary fibrosis]] has been reported when bromocriptine was used in high doses for the treatment of Parkinson's disease.<ref>{{Cite journal
| journal = Clinical and experimental neurology
| volume = 27
| pages = 79–82
| year = 1990
| title = Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease
| last1 = Todman
| last2 = Oliver
| pmid = 2129961
| last3 = Edwards | first1 = D. | first2 = W. | first3 = R.
}}</ref>

Use to suppress milk production after childbirth was reviewed in 2014 and it was concluded that in this context a causal association with serious cardiovascular, neurological or psychiatric events could not be excluded with an overall incidence rate estimated to range between 0.005% and 0.04%. Additional safety precautions and stricter prescribing rules were suggested based on the data.<ref>[http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/08/news_detail_002157.jsp&mid=WC0b01ac058004d5c1 EMA Statement "CMDh endorses restricted use of bromocriptine for stopping breast milk production"]</ref><ref>http://m.aerzteblatt.de/news/59857.htm "EMA rät vom Abstillmittel Bromocriptin ab", article in [[Ärzteblatt]]</ref>  It is a bile salt export pump inhibitor.<ref>{{cite journal |last1=Montanari |first1=Floriane |last2=Pinto |first2=Marta |last3=Khunweeraphong |first3=Narakorn |last4=Wlcek |first4=Katrin |last5=Sohail |first5=M. Imran |last6=Noeske |first6=Tobias |last7=Boyer |first7=Scott |last8=Chiba |first8=Peter |last9=Stieger |first9=Bruno |last10=Kuchler |first10=Karl |last11=Ecker |first11=Gerhard F. |title=Flagging Drugs That Inhibit the Bile Salt Export Pump |journal=Molecular Pharmaceutics |volume=13 |issue=1 |pages=163–71 |year=2016 |pmid=26642869 |doi=10.1021/acs.molpharmaceut.5b00594 }}</ref>

After long-term use of [[dopamine agonist]]s, a [[withdrawal syndrome]] may occur during dose reduction or discontinuation with the following possible side effects:  anxiety, panic attacks, [[dysphoria]], depression, agitation, irritability, suicidal ideation, fatigue, [[orthostatic hypotension]], nausea, vomiting, [[diaphoresis]], generalized pain, and drug cravings. For some individuals, these withdrawal symptoms are short-lived and they make a full recovery, for others a [[protracted withdrawal syndrome]] may occur with withdrawal symptoms persisting for months or years.<ref name="pmid23686524">{{cite journal |vauthors=Nirenberg MJ |title=Dopamine agonist withdrawal syndrome: implications for patient care |journal=Drugs Aging |volume=30 |issue=8 |pages=587–92 |year=2013 |pmid=23686524 |doi=10.1007/s40266-013-0090-z }}</ref>

==Pharmacology==
Bromocriptine is a potent agonist at [[dopamine]] D2 receptors<ref>{{Cite journal 
| last1 = De Leeuw Van Weenen | first1 = J. E. 
| last2 = Parlevliet | first2 = E. T. 
| last3 = Maechler | first3 = P. 
| last4 = Havekes | first4 = L. M. 
| last5 = Romijn | first5 = J. A. 
| last6 = Ouwens | first6 = D. M. 
| last7 = Pijl | first7 = H. 
| last8 = Guigas | first8 = B. 
| doi = 10.1016/j.bcp.2010.01.029 
| title = The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells 
| journal = Biochemical Pharmacology 
| volume = 79 
| issue = 12 
| pages = 1827–36 
| year = 2010 
| pmid = 20138024 
| pmc = 
}}</ref> and various [[serotonin]] receptors. It also inhibits the release of [[glutamate]], by reversing the glutamate [[GLT1]] transporter.<ref>{{cite journal|last1=Shirasaki|first1=Y|last2=Sugimura|first2=M|last3=Sato|first3=T|title=Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal.|journal=European Journal of Pharmacology|date=September 2010|volume=643|issue=1|pages=48–57|doi=10.1016/j.ejphar.2010.06.007|pmid=20599932}}</ref>

Bromocriptine agonizes the following monoamine receptors:<ref>National Institute ofMental Health. PDSD Ki&nbsp;Database (Internet) [cited 2013 Jul 24]. ChapelHill (NC): University of North Carolina. 1998-2013. Available from:&nbsp;{{cite web|url=http://pdsp.med.unc.edu/pdsp.php |title=Archived copy |accessdate=2013-11-26 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=2013-11-08 |df= }}</ref>

*'''Dopamine D<sub>1</sub> family'''
**[[Dopamine D1 receptor|D<sub>1</sub>]] (K<sub>i</sub>=682 nM)
**[[Dopamine D5 receptor|D<sub>5</sub>]] (K<sub>i</sub>=496 nM)
*'''Dopamine D<sub>2</sub> family'''
**[[Dopamine D2 receptor|D<sub>2</sub>]] (K<sub>i</sub>=2.96 nM)
**[[Dopamine D3 receptor|D<sub>3</sub>]] (K<sub>i</sub>=5.42 nM)
**[[Dopamine D4 receptor|D<sub>4</sub>]] (K<sub>i</sub>=328 nM)
*'''Serotonin''' ''5-HT''
**[[5-HT1A receptor|5-HT<sub>1A</sub>]] (K<sub>i</sub>=12.9 nM)
**[[5-HT1B receptor|5-HT<sub>1B</sub>]] (K<sub>i</sub>=355 nM)
**[[5-HT1D receptor|5-HT<sub>1D</sub>]] (K<sub>i</sub>=10.7 nM)
**[[5-HT2A receptor|5-HT<sub>2A</sub>]] (K<sub>i</sub>=107 nM)
**[[5-HT2B receptor|5-HT<sub>2B</sub>]] (K<sub>i</sub>=56.2 nM)
**[[5-HT2C receptor|5-HT<sub>2C</sub>]] (K<sub>i</sub>=741 nM)
**[[5-HT6 receptor|5-HT<sub>6</sub>]] (K<sub>i</sub>=33 nM)
*'''Adrenergic α family'''
**[[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] (K<sub>i</sub>=4.17 nM)
**[[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] (K<sub>i</sub>=1.38 nM)
**[[Alpha-1D adrenergic receptor|α<sub>1D</sub>]] (K<sub>i</sub>=1.12 nM)
**[[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] (K<sub>i</sub>=11.0 nM)
**[[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] (K<sub>i</sub>=34.7 nM)
**[[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] (K<sub>i</sub>=28.2 nM)
*'''Adrenergic β family'''
**[[Beta-1 adrenergic receptor|β<sub>1</sub>]] (K<sub>i</sub>=589 nM)
**[[Beta-2 adrenergic receptor|β<sub>2</sub>]] (K<sub>i</sub>=741 nM)

== Chemistry ==
Like all [[ergoline|ergopeptides]], bromocriptine is a [[cyclol]]; two peptide groups of its tri[[peptide]] moiety are crosslinked, forming the >N-C(OH)< juncture between the two rings with the [[amide]] [[functional group|functionality]].

Bromocriptine is a [[semisynthetic]] derivative of a natural [[ergot]] [[alkaloid]], [[ergocryptine]] (a derivative of [[lysergic acid]]), which is synthesized by bromination of ergocryptine using [[N-Bromosuccinimide|''N''-bromosuccinimide]].<ref>E. Fluckiger, A. Hofmann, {{US Patent|3752814}} (1973)</ref><ref>A. Hofmann, E. Flueckiger, {{Cite patent|DE|1926045}} (1969)</ref>

[[File:Bromocriptine synthesis.png|400px]]

==History==
Bromocriptine was discovered by scientists at [[Sandoz]] in 1965 and was first published in 1968; it was first marketed under the brand name Parlodel.<ref>{{cite book|last1=Sneader|first1=Walter|last2=Corey|first2=E. J.|title=Drug Discovery: A History|date=2005|publisher=John Wiley & Sons|isbn=9780471899792|page=352|url=https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA352|language=en}}</ref><ref>{{cite journal|last1=Beekman|first1=Andrew M.|last2=Barrow|first2=Russell A.|title=Fungal Metabolites as Pharmaceuticals|journal=Australian Journal of Chemistry|date=2014|volume=67|issue=6|pages=827|doi=10.1071/CH13639}}</ref>

A quick-release formulation of bromocriptine was approved by the FDA in 2009.<ref>{{cite journal|last1=Holt|first1=RI|last2=Barnett|first2=AH|last3=Bailey|first3=CJ|title=Bromocriptine: old drug, new formulation and new indication.|journal=Diabetes Obes Metab.|date=December 2010|volume=12|issue=12|pages=1048–57|doi=10.1111/j.1463-1326.2010.01304.x|pmid=20977575}}</ref>

==Society and culture==
As of July 2017, bromocriptine was marketed under many brand names worldwide, including Abergin, Barlolin, Brameston, Brocriptin, Brom, Broma-Del, Bromergocryptine, Bromergon, Bromicon, Bromocorn, Bromocriptin, Bromocriptina, Bromocriptine, Bromocriptine mesilate, Bromocriptine mesylate, Bromocriptine methanesulfonate, Bromocriptini mesilas, Bromocriptinmesilat, Bromodel, Bromokriptin, Bromolac, Bromotine, Bromtine, Brotin, Butin, Corpadel, Cripsa, Criptine, Criten, Cycloset, Degala, Demil, Deparo, Deprolac, Diacriptin, Dopagon, Erenant, Grifocriptina, Gynodel, kirim, Kriptonal, Lactodel, Medocriptine, Melen, Padoparine, Palolactin, Parlodel, Pravidel, Proctinal, Ronalin, Semi-Brom, Serocriptin, Serocryptin, Suplac, Syntocriptine, Umprel, Unew, Updopa, Upnol B, and Volbro.<ref name=brands>{{cite web|title=Bromocriptine international brand names|url=https://www.drugs.com/international/bromocriptine.html|publisher=Drugs.com|accessdate=13 July 2017}}</ref>

As of July 2017 it was also marketed as a [[combination drug]] with [[metformin]] as Diacriptin-M, and as a veterinary drug under the brand Pseudogravin.<ref name=brands/>

== See also ==
* [[Cabergoline]]

== References ==
{{Reflist|2}}

== External links ==
* [https://web.archive.org/web/20090822125308/http://www.acromegalycommunity.com/content/pages/acromegaly-drug-info www.AcromegalyCommunity.com: Emotional and communal support for those touched by Acromegaly- page discussing drug, side effects, and prescription programs]
* {{MedlinePlusDrugInfo|medmaster|a682079}}
* http://www.drugs.com/pro/bromocriptine.html

{{Antiparkinson}}
{{Oral hypoglycemics and insulin analogs}}
{{Other gynecologicals}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Ergolines}}

[[Category:5-HT2B agonists]]
[[Category:Dopamine agonists]]
[[Category:Lysergamides]]
[[Category:Organobromides]]
[[Category:Oxazolopyrrolopyrazines]]
[[Category:Serotonin receptor agonists]]